Plain-English translation of NCT05736419 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Sickle Cell Disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether and —medications that calm down your immune system—can help protect people with sickle cell disease or beta-thalassemia when they receive a stem cell transplant from a half-matched family donor. The study doctors think giving these medications before the standard transplant procedure may prevent serious complications like transplant rejection or graft-versus-host disease. Depending on how your body responds, you may also receive additional immune-suppressing drugs to improve your chances of a successful transplant.
Stem cell transplants can cure sickle cell disease and beta-thalassemia, but they often cause serious and life-threatening side effects. This trial exists to see whether starting with immune-suppressing medications before the transplant can make the procedure safer and more effective.
You likely qualify if…
You likely don't qualify if…
You will receive and as pre-treatment medications, with the possibility of additional immune-suppressing drugs based on your blood test results and how you respond. After this pre-treatment phase, you will undergo the standard conditioning therapy and receive stem cells from your half-matched donor. Your doctors will monitor you closely throughout the process with blood tests, imaging, and regular clinic visits to watch for side effects and measure how well the transplant is working.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States